25 results on '"Gavini, M."'
Search Results
2. Acknowledgement to reviewers of social sciences in 2019
- Author
-
Abbas, A., Abel, G., Abreu, A., Adam, A., Adamek, M., Adiletta, G., Adusei-asante, K.A., Romeo, M.D.M., Alderson, A., Alfaro, E., Aliverti, A., Almeida, Fernando, Álvarez-gonzález, L.I., Amelina, A., Anand, C., Anderson, G., Andreasson, J., Ang, I., Aragon, J., Arcidiacono, C., Arcuri, S., Assante, D., Atukeren, E., Avery, H., Ayeb-karlsson, S., Azadi, H., Bachman, R., Bader, M., Badulescu, A., Bahmanteymouri, E., Baines, S., Baker, T., Baker‐beall, C., Bañón, L., Bar‐am, N., Barbier‐greenland, K., Barnett, R., Barragán‐escandón, A., Barreto, A.M., Barrett, E., Bartkowski, J., Bartram, R., Bartzas, G., Bates, D., Baviera‐puig, A., Bayley, A., Beazley, H., Beer, C., Behr, H., Beier, G., Belford, N., Bencivenga, R., Benli, A.E., Benton‐short, L., Berei, J.M., Berbel‐pineda, E., Bernstein, Berntzen, E.R., Bertella, L., Birney, G., Bittle, M., Black, S., Rivero, L.B., Blattner, J.J., Blok, C., Blount, A., Boas, Y., Bockarie, I., Bockerman, A., Bodén, P., Bönisch‐brednich, L., Bontje, B., Bontje, M., Borsellino, V., Bostan, I., Bowl, M., Bowman, B., Bracci, E., Bracken, C.M., Bradley, H., Brereton, P., Brewer, J., Bridge, D., Brooks, S., Brown, Andrijana, Brzoska, M., Brzozowski, W., Buckley, G., Buente, W., Bullaro, G.R., Burke, M.D., Burlacu, S., Busu, M., Butler, S., Byrne, J., Cabral, L., Cai, Y., Cajias, M., Calin, A.C., Callegari, C., Camarero, M., Campbell-figuerola, H., Campbell, J.R., Cannito, M., Canonico, E., Canosa, A., Carabelli, G., Carlbom, A., Carlone, T., Caron, R., Carpenter, A., Caruso, G., Casais, B., Castro, M.P., Cava, M.-J., Čeněk, J., Cerchione, R., Certomà, C., Chan, E., Charles, D., Charlwood, A., Chatzifotiou, S., Chell, K., Chen, L., Chen, Q., Chen, W.-J., Ching, L., Christensen, J., Ciasullo, M.V., Cimermanová, I., Činčera, J., Cipollina, M., Clutterbuck, R., Cochrane, B., Collin, K., Conley, R., Connell, H., Connelly, J., Connelly, L., Connelly, R., Conti, D., Conversi, D., Conway, G., Cooper, S., Cope, M., Corsini, F., Cristian, P., Crohn, H.M., Croog, R.C., Salazar, T., Csiszár, C., D’auria, I., D’souza, A., D’souza, N., Dabija, D.-C., Dagg, J., Dalby, S., DaleDalsgård, B., Dʹamato, A.L., Daniel, D., Dant, L., Dantas, C., Darwin, H., Dashper, K., David, M.E., De Flippo, D., De, A., Edi, M., Velázquez, E.D.C., Velázquez, F., Del Vecchio, P., Delatolla, A., Delgado, P., Delgado‐romero, E., Delrosso, J., Desimone, J., Detlefsen, L., Devaney, C., Díaz, L.M., Didham, R., Diogo, E., Dirakis, A., Doberneck, D., Doidge, M.D., Molero, G., Dombrowski, P.J., Doñate, C., Đorđević, Martín, Reis, P.G.R., Doucek, P., Dundes, L., Dvouletý, O., Dybo, T., Eastman, J., Eckhardt, J., Economou, A., Edler, D., Edu, U., Ekblom, P.E., Khaled, D., Ellis, C., Elsabry, E., Erceg, A., Erokhin, V., Ertz, M., Everitt, J., Evers, A., Falcone, P.M.F., Cabana, P., Fawcett, B., Fearnley, B., Featherstone, M., Ferreira, M., Ferreira, P., Fetner, T., Fisher, J., Fisher, R., Fitzpatrick, T., Flanagan, C., Fogarty, E.A., Fonchingong, C.C., Fontana, M., Fook, J., Foreman, A.M., Foster‐mcgregor, N., Fox, S., Franco, J.A., Franklin, A.L., Friedrich, T., Fromm, I., Fu, N., Fucà, R., Fukuda, Y., Fusco, G., Gabriela, D., Galan, D., Gamo, A., Galiano, J., Garcia, A., García, M.E.A., García‐germán, S., García‐machado, J.J., García‐ruiz, C.R., Gavini, M., Gazzano, A., Gebhardt, M., Gerson, S., Gherghina, Ş.C., Gibbs, P., Gilhooly, D., Gill, F., Gill, N., Gil‐lopez, A.J., Ginès Fabrellas, A., Giuffrida, N., Giuliani, G., Goddard, J., Godderis, R., Goh, C.S., Gomes, O., Goncharuk, A.G., Canche, M.G., Pérez, I.G., Valero, G., González, R.C.L., Gonzalez‐benson, O., Gonzalez‐feliu, J., González‐lópez, M., Gozdziak, E., Granx, B., Gran, R., Gray, S.L., Grbes, A., Grondys, K., Grugan, S., Guenther, J., Guijarro, F., Gurko, T., Haas, L.L., Hagellx, A., Hagell, H., Hallgrímsdóttir, H., Hamada, T., Hanf, J., Hannouf, M., Hao, F., Harman, G., Harris, K.L., Harris, R., Harrison, N.H., Healy, G., Healy, K., Heikkilä, E., Hellmich, C., Henig, J., Henninger, C.E., Heo, W., Herman, C., Herrero‐diz, P., Heyman, J., Hibbert, N., Hillman, A.L., Hillman, B., Hine, B., Hino, K., Hinten, M., Hipp, L., Hoang, D., Holleran, D., Hollin, I., Holm, M., Holmes, C., Hook, G., Hoornweg, D., Hopper, L., Hossain, M., Hoxhaj, R., Hu, B., Huang, Y., Huarita, E., Hudec, O., Humbert, A.L., Hung, M.-C., Hunt, A., Husu, L., IanoleIbáñez‐gonzález, R., Ibáñez‐gonzález, M.J., Ide, T., Ijaz, Muhammad Fazal, Impicciatore, R., Ingwersen, M., Ioannides, D., Iseppi, L., Islam, M.M., Jaakkola, M., Jagger, S., Jagosh, J., Jenkin, G., Joelsson, T., Johansen, R.E.B., Johnsen, H.C., Garmann Jona, G., Jones, T., Judit, O., Kalalahti, M., Kang, M., Kantamaneni, K., Kaplan, L., Kapsalis, V., Karbowski, A., Katsoni, V., Kavish, D.R., Kawamura, H., Keilman, N.W., Kelly, J., Kenneth, H., Kepaptsoglou, K., Kevin, D., Kewley, S., Kim, J.-C., Kim, K.-Y., Kim, S., Kimengsi, J.N., Klein, J., Kleine, M., Klemes, J.I.R.I., Klepp, S., Klinkenberg, L.E.F., Knight, L., Knowles, J., Koerner, S., Konsolakis, K., Konstantinov, V., Kopkin, N.K., Kordova, S., Kosinski, E., Kostelka, F., Kot, S., Kotter, R., Kramers, A., Krienert, J.L., Kubon, M., Kuffer, M., Kungolos, A., Kuttner, P., Kużelewska, E., Ladd, A.E., Lammi, M., Landrum, J., Lange, B., Languilaire, T.D., Lantz, J.-C., Laudal, B., Laurentsyeva, T., Lavizzari, N., Lavoie, A., Feuvre, J.L., Leakey, N., Lee, R., Lee, A., Lee, E., Lee, J., Lentner, J.-H., Lenz‐taguchi, C., Leong, H., Levac, W.S., Lewin, L., Lewinson, E., Li, T., Li, F., Li, G., Li, M., Liczmańska‐kopcewicz, Y., Lillard, K., Linková, C., Links, M., Lipinski, P., Storto, J.L., Lochtman, C., Lockwood, K., Loh, A., Lomonaco‐benzing, V., Łopaciuk‐gonczaryk, R., López, B., lópez, D., Lorenzini, J., Löther, A., Loughnan, C., Love, T., Lucas, M.L., Ubago, J., Lukić, J., Lumley‐sapanski, A., Macedo, I., Macfarlane, S., Machimbarrena, J.M., Magda, R., Magrane, D., Maier, D., Majić, S., Majumdar, S., Makarovič, M., Malekigorji, M., Mallick, B., Malone, D., Mandić, D., Maniou, T., Mannell, J.M., Barbutiu, S., Marczak, M., Markvica, K.M., Aragón, M.D.M., Martín, J.S.M., Pereira, A., Marzal‐felici, J., Mason, F., Mather, J., Matijosaitiene, I., MatthewsMattisson, R., Mattisson, C., Matuszak, Ł., Matuzeviciute, K., Mauerer, G., Mayer, A., McCaig, C., McClearn, D., McKee, S.C., McKendry, S., McMahon, M., McReynolds, P., Medina‐vicent, M., Medyna, G., Mees, H., Meil, G., Meringolo, P., Miciuła, I., Milczarek‐andrzejewska, D., Miles, P., Milivojević, S., Miller, G., Minello, A., Miron, D., Mironeasa, S., Misra, J., Mitchell, T., Moldovan, O., Molero, P.P., Møllersen, S., Momsen, J.H., Moniz, A.B., Morea, D., Moreau, M.-P., Morgan, D.L., Morgan, H., Moscatelli, S., Mostowska, M., Mousavi, A., Mousavi, S., Mrugalska, B., Muinos, G., Mukungu, K., Mukuni, J., Murakami, D., Muresan, I.C., Murib, Z., Muro, A., Mustafa, G., Nackerud, L., Nalmpantis, D., Napal, M., Närvi, J., Naser, M., Nash, V., Navarre‐jackson, L., Navarro, R., Nazarczuk, D., Neale, J., Necula, J., Němec, S., Neven, D., Nevgi, A., Newbold, A., Newton, G., New, A., Niakšu, O., Niiniluoto, I., Nkogo, J.C., Nobre, S., Nunn, P., Oakes, R., Obrad, C., Oke, A., Okorie, O., Oncioiu, I., Ormsbee, F., Ortega‐sánchez, D., Osgood, J., Osorio, C., Oswald, J., Otis, M.D., Ouassini, A., Oxford, S., Page, T., Paixão, M.J., De Pajares, E.M., Palmesr, E., Palos‐sánchez, P., Pamučar, Dragan, Pan, H., Panek, J., Pankowska, M., Papadakis, S., Papafilippou, V.P., Medina, R., Park, C.S., Partalidou, M., Passantino, A., Passini, S., Paul, S., Pavliuk, R., Pearce, P., Pease, K., Pentaris, P., Perez, V.W., Pérez‐armendáriz, C., Perez‐vaisvidovsky, N., Perez‐y‐perez, M., Perry, N., Prtchu, D., Peterson, D.A.M., Alexandru‐ionut, Petrykowski, Petrykowski, P., Phillips, L., Pickard, S., Pickel, A., Pieke, F., Piekut, A., Pierce, S., Pierrakis, Y., Piguet, E., Pleace, N., Połom, M., Polsa, P., Ponticorvo, M., Pookulangara, S., Pope, J., Popoli, P., Postigo, J.C., Price‐Wolf, J., Prior, S., Privitera, D., Prud’homme, C., Prosser, J., Prus, P., Puiu, S., Purcell, R., Pyrialakou, D., Quam‐wickham, N., Quarmby, T., Quinlan, K.M., Quinn, A., Quinn, R., Raciti, M., Radicić, D., Rahimi, B., Ramlo, S., Randle, H., Ratajczak, M., Raymond, T., Recio‐menéndez, M., Reese, L.A., Regner, T., Reichman, J., WReim, iebke, R., Pastor, A.M., Rexhepi, G., Reyes‐menendez, A., Reynaud, C., Ribeiro‐soriano, D., Ricci, S., Ridaura, G., Rita, C., Roberts, M., Roberts, G., Roberts, K., Rockerbie, D., Rodger, J.A., Rodin, G., Rodrigues, D.R., Martín, J.A., Rodríguez, C.F., Rodriguez‐modroño, P., Romero‐rodríguez, L.M., Rončáková, T., Roper, I., Rorie, M.R., Marzán, C.F., Rose, G., Rose, M., Rosen, R., Roth, R., Roubík, H., Roumpos, C., Rowbottom, D., Roy, J., Ruban, D., Rubira‐garcía, R., Ruiperez‐valiente, J.A., Ruiz, R., Ruiz‐real, J.L., Russell, B., Russo, K., Sabol, W., Safonte, F., Salin, M., Salom‐carrasco, J.S., Sánchez, L.D., Sanghera, Santos, B.S., Silva, D., Sanz, F., Sanz‐altamira, B., Sarapura, S., Sari, D., Satybaldieva, E., Saura, J.R., Sayed, N., Scandurra, C., Schartner, A., Schellekens, J., Schenk‐hoppé, K.R., Scherer, L., Schewe, J.A., Schewe, R., Schiller, N.G., Schmidt, E.-M., Schneickert, C., Schneider, J., Scott, H., Scott, P., Seibel, K., Seidler, R., Seifert, S.S., Puyuelo, M.S., Azevedo, P.S., Lopez, A.E.S., Raamkumar, A.S., Blundo, D., Severo, M., Shakya, K.M., Shapiro, A., Shaw, I.F., Shaw, T.V., Shea, B., Shearer, H., Sheldon, S., Shell‐duncan, B., Shepherd, S., Sheridan, L., Siemienska, R., Sillup, G.P., Simeon, J.C., Simonelli, A., Skilodimou, H.D., Škrinjarić, T., Slater, G., Smardon, R., Smith, J., Smoląg, K., Snauwaert, D.T., Soanes‐white, T., Sobocińska, M., Sohaib, O., Soldatić, K., Sorainen, G.T., Soldatos, A., Sørensen, N.N., Spanu, S., Stadlober, E., Stafford, F., Ștefănescu‐mihăilă, R.O., Stefanini, A., Štefko, R., Steglich, E., Steirer, G., Stephenson, M.O., Stoecker, R., Stoffelen, A., Strang, A., Suppa, D., Sutton, J., Svobodová, L., Swigon, M., Synnott, J., Sytsma, V., Tabe, T., Tajeddini, K., Tang, S., Taylor, B., Taylor, C., Teignier, M., Teixeira, C., Tempelaar, D., Ter Avest, K.H., Ter Horst, E., Testa, M.R., Thakur, N., Thiamwong, L., Thijsen, A., Thomas, B.A., Thompson, C., Thompson, D., Tisdall, K., Toft, Mancini, Torell, A., Toscano‐hernández, G., Tregua, A.E., Triandafyllidou, M., Tseloni, A., Seloni, A., Tsikouras, P., Tsogas, G., Twamley, K., Tyler, D.U., Haque, A., Underwood, M., Urbański, M., Uribe‐toril, J., Vaezipour, A., Van Hove, L.V., Huylenbroeck, G., Van Nuland, S., Vanner, C., Vázquez‐cano, E., Veen, E., Veintimilla, S.G.-A., Veković, M., Velija, P., Venco, E.M., Verticelli, A., Vicente, P.V., Estiarte, C., Višnjić, A., Visvizi, A., Vlasblom, J.D., Volsche, S.V., Fintel, D., Von Keyserlingk, L., Vranješević, J., Walter, K.V., Wandosell, G., Wang, Y., Wasileski, G., Wastl‐walter, D., Weaving, C., Weenik, D., Wehr, K., Wei, X., Wharton, A., White, G., Whitehouse, H., Whitley, C.T., Whitman, L., Wiersma‐mosley, J.D., Wilcke, H., Wilkes, R., Williams, L., Williamson, R.D., Wimalasena, L., Wiseman, A., Wołek, M., Wright, E.Q., Wroblewski, A., Wyile, A.S., Wynn, C., Xu, X., Xue, B., Yang, J., Yoe, T.M., Young, M., Younus, M., Yu, T.-F., Yuan, Q., Zadra, C., Zaharijević, A., Zajda, J., Zander, K., Zbuchea, A., Zelin, A., Zhang, C., Zippel, K., Zitricky, V., Živanović, P., Zou, L., Zufferey, C., Zuhdi, M., Zumeta, W.M., Abbas, A., Abel, G., Abreu, A., Adam, A., Adamek, M., Adiletta, G., Adusei-asante, K.A., Romeo, M.D.M., Alderson, A., Alfaro, E., Aliverti, A., Almeida, Fernando, Álvarez-gonzález, L.I., Amelina, A., Anand, C., Anderson, G., Andreasson, J., Ang, I., Aragon, J., Arcidiacono, C., Arcuri, S., Assante, D., Atukeren, E., Avery, H., Ayeb-karlsson, S., Azadi, H., Bachman, R., Bader, M., Badulescu, A., Bahmanteymouri, E., Baines, S., Baker, T., Baker‐beall, C., Bañón, L., Bar‐am, N., Barbier‐greenland, K., Barnett, R., Barragán‐escandón, A., Barreto, A.M., Barrett, E., Bartkowski, J., Bartram, R., Bartzas, G., Bates, D., Baviera‐puig, A., Bayley, A., Beazley, H., Beer, C., Behr, H., Beier, G., Belford, N., Bencivenga, R., Benli, A.E., Benton‐short, L., Berei, J.M., Berbel‐pineda, E., Bernstein, Berntzen, E.R., Bertella, L., Birney, G., Bittle, M., Black, S., Rivero, L.B., Blattner, J.J., Blok, C., Blount, A., Boas, Y., Bockarie, I., Bockerman, A., Bodén, P., Bönisch‐brednich, L., Bontje, B., Bontje, M., Borsellino, V., Bostan, I., Bowl, M., Bowman, B., Bracci, E., Bracken, C.M., Bradley, H., Brereton, P., Brewer, J., Bridge, D., Brooks, S., Brown, Andrijana, Brzoska, M., Brzozowski, W., Buckley, G., Buente, W., Bullaro, G.R., Burke, M.D., Burlacu, S., Busu, M., Butler, S., Byrne, J., Cabral, L., Cai, Y., Cajias, M., Calin, A.C., Callegari, C., Camarero, M., Campbell-figuerola, H., Campbell, J.R., Cannito, M., Canonico, E., Canosa, A., Carabelli, G., Carlbom, A., Carlone, T., Caron, R., Carpenter, A., Caruso, G., Casais, B., Castro, M.P., Cava, M.-J., Čeněk, J., Cerchione, R., Certomà, C., Chan, E., Charles, D., Charlwood, A., Chatzifotiou, S., Chell, K., Chen, L., Chen, Q., Chen, W.-J., Ching, L., Christensen, J., Ciasullo, M.V., Cimermanová, I., Činčera, J., Cipollina, M., Clutterbuck, R., Cochrane, B., Collin, K., Conley, R., Connell, H., Connelly, J., Connelly, L., Connelly, R., Conti, D., Conversi, D., Conway, G., Cooper, S., Cope, M., Corsini, F., Cristian, P., Crohn, H.M., Croog, R.C., Salazar, T., Csiszár, C., D’auria, I., D’souza, A., D’souza, N., Dabija, D.-C., Dagg, J., Dalby, S., DaleDalsgård, B., Dʹamato, A.L., Daniel, D., Dant, L., Dantas, C., Darwin, H., Dashper, K., David, M.E., De Flippo, D., De, A., Edi, M., Velázquez, E.D.C., Velázquez, F., Del Vecchio, P., Delatolla, A., Delgado, P., Delgado‐romero, E., Delrosso, J., Desimone, J., Detlefsen, L., Devaney, C., Díaz, L.M., Didham, R., Diogo, E., Dirakis, A., Doberneck, D., Doidge, M.D., Molero, G., Dombrowski, P.J., Doñate, C., Đorđević, Martín, Reis, P.G.R., Doucek, P., Dundes, L., Dvouletý, O., Dybo, T., Eastman, J., Eckhardt, J., Economou, A., Edler, D., Edu, U., Ekblom, P.E., Khaled, D., Ellis, C., Elsabry, E., Erceg, A., Erokhin, V., Ertz, M., Everitt, J., Evers, A., Falcone, P.M.F., Cabana, P., Fawcett, B., Fearnley, B., Featherstone, M., Ferreira, M., Ferreira, P., Fetner, T., Fisher, J., Fisher, R., Fitzpatrick, T., Flanagan, C., Fogarty, E.A., Fonchingong, C.C., Fontana, M., Fook, J., Foreman, A.M., Foster‐mcgregor, N., Fox, S., Franco, J.A., Franklin, A.L., Friedrich, T., Fromm, I., Fu, N., Fucà, R., Fukuda, Y., Fusco, G., Gabriela, D., Galan, D., Gamo, A., Galiano, J., Garcia, A., García, M.E.A., García‐germán, S., García‐machado, J.J., García‐ruiz, C.R., Gavini, M., Gazzano, A., Gebhardt, M., Gerson, S., Gherghina, Ş.C., Gibbs, P., Gilhooly, D., Gill, F., Gill, N., Gil‐lopez, A.J., Ginès Fabrellas, A., Giuffrida, N., Giuliani, G., Goddard, J., Godderis, R., Goh, C.S., Gomes, O., Goncharuk, A.G., Canche, M.G., Pérez, I.G., Valero, G., González, R.C.L., Gonzalez‐benson, O., Gonzalez‐feliu, J., González‐lópez, M., Gozdziak, E., Granx, B., Gran, R., Gray, S.L., Grbes, A., Grondys, K., Grugan, S., Guenther, J., Guijarro, F., Gurko, T., Haas, L.L., Hagellx, A., Hagell, H., Hallgrímsdóttir, H., Hamada, T., Hanf, J., Hannouf, M., Hao, F., Harman, G., Harris, K.L., Harris, R., Harrison, N.H., Healy, G., Healy, K., Heikkilä, E., Hellmich, C., Henig, J., Henninger, C.E., Heo, W., Herman, C., Herrero‐diz, P., Heyman, J., Hibbert, N., Hillman, A.L., Hillman, B., Hine, B., Hino, K., Hinten, M., Hipp, L., Hoang, D., Holleran, D., Hollin, I., Holm, M., Holmes, C., Hook, G., Hoornweg, D., Hopper, L., Hossain, M., Hoxhaj, R., Hu, B., Huang, Y., Huarita, E., Hudec, O., Humbert, A.L., Hung, M.-C., Hunt, A., Husu, L., IanoleIbáñez‐gonzález, R., Ibáñez‐gonzález, M.J., Ide, T., Ijaz, Muhammad Fazal, Impicciatore, R., Ingwersen, M., Ioannides, D., Iseppi, L., Islam, M.M., Jaakkola, M., Jagger, S., Jagosh, J., Jenkin, G., Joelsson, T., Johansen, R.E.B., Johnsen, H.C., Garmann Jona, G., Jones, T., Judit, O., Kalalahti, M., Kang, M., Kantamaneni, K., Kaplan, L., Kapsalis, V., Karbowski, A., Katsoni, V., Kavish, D.R., Kawamura, H., Keilman, N.W., Kelly, J., Kenneth, H., Kepaptsoglou, K., Kevin, D., Kewley, S., Kim, J.-C., Kim, K.-Y., Kim, S., Kimengsi, J.N., Klein, J., Kleine, M., Klemes, J.I.R.I., Klepp, S., Klinkenberg, L.E.F., Knight, L., Knowles, J., Koerner, S., Konsolakis, K., Konstantinov, V., Kopkin, N.K., Kordova, S., Kosinski, E., Kostelka, F., Kot, S., Kotter, R., Kramers, A., Krienert, J.L., Kubon, M., Kuffer, M., Kungolos, A., Kuttner, P., Kużelewska, E., Ladd, A.E., Lammi, M., Landrum, J., Lange, B., Languilaire, T.D., Lantz, J.-C., Laudal, B., Laurentsyeva, T., Lavizzari, N., Lavoie, A., Feuvre, J.L., Leakey, N., Lee, R., Lee, A., Lee, E., Lee, J., Lentner, J.-H., Lenz‐taguchi, C., Leong, H., Levac, W.S., Lewin, L., Lewinson, E., Li, T., Li, F., Li, G., Li, M., Liczmańska‐kopcewicz, Y., Lillard, K., Linková, C., Links, M., Lipinski, P., Storto, J.L., Lochtman, C., Lockwood, K., Loh, A., Lomonaco‐benzing, V., Łopaciuk‐gonczaryk, R., López, B., lópez, D., Lorenzini, J., Löther, A., Loughnan, C., Love, T., Lucas, M.L., Ubago, J., Lukić, J., Lumley‐sapanski, A., Macedo, I., Macfarlane, S., Machimbarrena, J.M., Magda, R., Magrane, D., Maier, D., Majić, S., Majumdar, S., Makarovič, M., Malekigorji, M., Mallick, B., Malone, D., Mandić, D., Maniou, T., Mannell, J.M., Barbutiu, S., Marczak, M., Markvica, K.M., Aragón, M.D.M., Martín, J.S.M., Pereira, A., Marzal‐felici, J., Mason, F., Mather, J., Matijosaitiene, I., MatthewsMattisson, R., Mattisson, C., Matuszak, Ł., Matuzeviciute, K., Mauerer, G., Mayer, A., McCaig, C., McClearn, D., McKee, S.C., McKendry, S., McMahon, M., McReynolds, P., Medina‐vicent, M., Medyna, G., Mees, H., Meil, G., Meringolo, P., Miciuła, I., Milczarek‐andrzejewska, D., Miles, P., Milivojević, S., Miller, G., Minello, A., Miron, D., Mironeasa, S., Misra, J., Mitchell, T., Moldovan, O., Molero, P.P., Møllersen, S., Momsen, J.H., Moniz, A.B., Morea, D., Moreau, M.-P., Morgan, D.L., Morgan, H., Moscatelli, S., Mostowska, M., Mousavi, A., Mousavi, S., Mrugalska, B., Muinos, G., Mukungu, K., Mukuni, J., Murakami, D., Muresan, I.C., Murib, Z., Muro, A., Mustafa, G., Nackerud, L., Nalmpantis, D., Napal, M., Närvi, J., Naser, M., Nash, V., Navarre‐jackson, L., Navarro, R., Nazarczuk, D., Neale, J., Necula, J., Němec, S., Neven, D., Nevgi, A., Newbold, A., Newton, G., New, A., Niakšu, O., Niiniluoto, I., Nkogo, J.C., Nobre, S., Nunn, P., Oakes, R., Obrad, C., Oke, A., Okorie, O., Oncioiu, I., Ormsbee, F., Ortega‐sánchez, D., Osgood, J., Osorio, C., Oswald, J., Otis, M.D., Ouassini, A., Oxford, S., Page, T., Paixão, M.J., De Pajares, E.M., Palmesr, E., Palos‐sánchez, P., Pamučar, Dragan, Pan, H., Panek, J., Pankowska, M., Papadakis, S., Papafilippou, V.P., Medina, R., Park, C.S., Partalidou, M., Passantino, A., Passini, S., Paul, S., Pavliuk, R., Pearce, P., Pease, K., Pentaris, P., Perez, V.W., Pérez‐armendáriz, C., Perez‐vaisvidovsky, N., Perez‐y‐perez, M., Perry, N., Prtchu, D., Peterson, D.A.M., Alexandru‐ionut, Petrykowski, Petrykowski, P., Phillips, L., Pickard, S., Pickel, A., Pieke, F., Piekut, A., Pierce, S., Pierrakis, Y., Piguet, E., Pleace, N., Połom, M., Polsa, P., Ponticorvo, M., Pookulangara, S., Pope, J., Popoli, P., Postigo, J.C., Price‐Wolf, J., Prior, S., Privitera, D., Prud’homme, C., Prosser, J., Prus, P., Puiu, S., Purcell, R., Pyrialakou, D., Quam‐wickham, N., Quarmby, T., Quinlan, K.M., Quinn, A., Quinn, R., Raciti, M., Radicić, D., Rahimi, B., Ramlo, S., Randle, H., Ratajczak, M., Raymond, T., Recio‐menéndez, M., Reese, L.A., Regner, T., Reichman, J., WReim, iebke, R., Pastor, A.M., Rexhepi, G., Reyes‐menendez, A., Reynaud, C., Ribeiro‐soriano, D., Ricci, S., Ridaura, G., Rita, C., Roberts, M., Roberts, G., Roberts, K., Rockerbie, D., Rodger, J.A., Rodin, G., Rodrigues, D.R., Martín, J.A., Rodríguez, C.F., Rodriguez‐modroño, P., Romero‐rodríguez, L.M., Rončáková, T., Roper, I., Rorie, M.R., Marzán, C.F., Rose, G., Rose, M., Rosen, R., Roth, R., Roubík, H., Roumpos, C., Rowbottom, D., Roy, J., Ruban, D., Rubira‐garcía, R., Ruiperez‐valiente, J.A., Ruiz, R., Ruiz‐real, J.L., Russell, B., Russo, K., Sabol, W., Safonte, F., Salin, M., Salom‐carrasco, J.S., Sánchez, L.D., Sanghera, Santos, B.S., Silva, D., Sanz, F., Sanz‐altamira, B., Sarapura, S., Sari, D., Satybaldieva, E., Saura, J.R., Sayed, N., Scandurra, C., Schartner, A., Schellekens, J., Schenk‐hoppé, K.R., Scherer, L., Schewe, J.A., Schewe, R., Schiller, N.G., Schmidt, E.-M., Schneickert, C., Schneider, J., Scott, H., Scott, P., Seibel, K., Seidler, R., Seifert, S.S., Puyuelo, M.S., Azevedo, P.S., Lopez, A.E.S., Raamkumar, A.S., Blundo, D., Severo, M., Shakya, K.M., Shapiro, A., Shaw, I.F., Shaw, T.V., Shea, B., Shearer, H., Sheldon, S., Shell‐duncan, B., Shepherd, S., Sheridan, L., Siemienska, R., Sillup, G.P., Simeon, J.C., Simonelli, A., Skilodimou, H.D., Škrinjarić, T., Slater, G., Smardon, R., Smith, J., Smoląg, K., Snauwaert, D.T., Soanes‐white, T., Sobocińska, M., Sohaib, O., Soldatić, K., Sorainen, G.T., Soldatos, A., Sørensen, N.N., Spanu, S., Stadlober, E., Stafford, F., Ștefănescu‐mihăilă, R.O., Stefanini, A., Štefko, R., Steglich, E., Steirer, G., Stephenson, M.O., Stoecker, R., Stoffelen, A., Strang, A., Suppa, D., Sutton, J., Svobodová, L., Swigon, M., Synnott, J., Sytsma, V., Tabe, T., Tajeddini, K., Tang, S., Taylor, B., Taylor, C., Teignier, M., Teixeira, C., Tempelaar, D., Ter Avest, K.H., Ter Horst, E., Testa, M.R., Thakur, N., Thiamwong, L., Thijsen, A., Thomas, B.A., Thompson, C., Thompson, D., Tisdall, K., Toft, Mancini, Torell, A., Toscano‐hernández, G., Tregua, A.E., Triandafyllidou, M., Tseloni, A., Seloni, A., Tsikouras, P., Tsogas, G., Twamley, K., Tyler, D.U., Haque, A., Underwood, M., Urbański, M., Uribe‐toril, J., Vaezipour, A., Van Hove, L.V., Huylenbroeck, G., Van Nuland, S., Vanner, C., Vázquez‐cano, E., Veen, E., Veintimilla, S.G.-A., Veković, M., Velija, P., Venco, E.M., Verticelli, A., Vicente, P.V., Estiarte, C., Višnjić, A., Visvizi, A., Vlasblom, J.D., Volsche, S.V., Fintel, D., Von Keyserlingk, L., Vranješević, J., Walter, K.V., Wandosell, G., Wang, Y., Wasileski, G., Wastl‐walter, D., Weaving, C., Weenik, D., Wehr, K., Wei, X., Wharton, A., White, G., Whitehouse, H., Whitley, C.T., Whitman, L., Wiersma‐mosley, J.D., Wilcke, H., Wilkes, R., Williams, L., Williamson, R.D., Wimalasena, L., Wiseman, A., Wołek, M., Wright, E.Q., Wroblewski, A., Wyile, A.S., Wynn, C., Xu, X., Xue, B., Yang, J., Yoe, T.M., Young, M., Younus, M., Yu, T.-F., Yuan, Q., Zadra, C., Zaharijević, A., Zajda, J., Zander, K., Zbuchea, A., Zelin, A., Zhang, C., Zippel, K., Zitricky, V., Živanović, P., Zou, L., Zufferey, C., Zuhdi, M., and Zumeta, W.M.
- Published
- 2020
3. A new radiochemical procedure for uranium assay in environmental samples
- Author
-
Gavini, M. B., Rocco, F. G., and Kim, S. M.
- Published
- 1981
- Full Text
- View/download PDF
4. Design of Glycoconjugate Vaccines against Invasive African Salmonella enterica Serovar Typhimurium
- Author
-
Rondini, S., primary, Micoli, F., additional, Lanzilao, L., additional, Gavini, M., additional, Alfini, R., additional, Brandt, C., additional, Clare, S., additional, Mastroeni, P., additional, Saul, A., additional, and MacLennan, C. A., additional
- Published
- 2015
- Full Text
- View/download PDF
5. Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard
- Author
-
Micoli, F., primary, Adamo, R., additional, Proietti, D., additional, Gavini, M., additional, Romano, M.R., additional, MacLennan, C.A., additional, Costantino, P., additional, and Berti, F., additional
- Published
- 2013
- Full Text
- View/download PDF
6. A scalable method for O-antigen purification applied to various Salmonella serovars
- Author
-
Micoli, F., primary, Rondini, S., additional, Gavini, M., additional, Pisoni, I., additional, Lanzilao, L., additional, Colucci, A.M., additional, Giannelli, C., additional, Pippi, F., additional, Sollai, L., additional, Pinto, V., additional, Berti, F., additional, MacLennan, C.A., additional, Martin, L.B., additional, and Saul, A., additional
- Published
- 2013
- Full Text
- View/download PDF
7. Relative stability of meningococcal serogroup A and X polysaccharides
- Author
-
Berti, F., primary, Romano, M.R., additional, Micoli, F., additional, Pinto, V., additional, Cappelletti, E., additional, Gavini, M., additional, Proietti, D., additional, Pluschke, G., additional, MacLennan, C.A., additional, and Costantino, P., additional
- Published
- 2012
- Full Text
- View/download PDF
8. Design of Glycoconjugate Vaccines against Invasive African Salmonella entericaSerovar Typhimurium
- Author
-
Rondini, S., Micoli, F., Lanzilao, L., Gavini, M., Alfini, R., Brandt, C., Clare, S., Mastroeni, P., Saul, A., and MacLennan, C. A.
- Abstract
ABSTRACTNontyphoidal salmonellae, particularly Salmonella entericaserovar Typhimurium, are a major cause of invasive disease in Africa, affecting mainly young children and HIV-infected individuals. Glycoconjugate vaccines provide a safe and reliable strategy against invasive polysaccharide-encapsulated pathogens, and lipopolysaccharide (LPS) is a target of protective immune responses. With the aim of designing an effective vaccine against S. Typhimurium, we have synthesized different glycoconjugates, by linking O-antigen and core sugars (OAg) of LPS to the nontoxic mutant of diphtheria toxin (CRM197). The OAg-CRM197conjugates varied in (i) OAg source, with three S. Typhimurium strains used for OAg extraction, producing OAg with differences in structural specificities, (ii) OAg chain length, and (iii) OAg/CRM197ratio. All glycoconjugates were compared for immunogenicity and ability to induce serum bactericidal activity in mice. In vivoenhancement of bacterial clearance was assessed for a selected S. Typhimurium glycoconjugate by challenge with live Salmonella. We found that the largest anti-OAg antibody responses were elicited by (i) vaccines synthesized from OAg with the highest glucosylation levels, (ii) OAg composed of mixed- or medium-molecular-weight populations, and (iii) a lower OAg/CRM197ratio. In addition, we found that bactericidal activity can be influenced by S. Typhimurium OAg strain, most likely as a result of differences in OAg O-acetylation and glucosylation. Finally, we confirmed that mice immunized with the selected OAg-conjugate were protected against S. Typhimurium colonization of the spleen and liver. In conclusion, our findings indicate that differences in the design of OAg-based glycoconjugate vaccines against invasive African S. Typhimurium can have profound effects on immunogenicity and therefore optimal vaccine design requires careful consideration.
- Published
- 2015
- Full Text
- View/download PDF
9. Temporal variations of 212Pb in thunderstorms.
- Author
-
Gavini, M. B., Holloway, R. W., Sherrill, R. D., Inn, K. G. W., and Kuroda, P. K.
- Published
- 1976
- Full Text
- View/download PDF
10. Plutonium isotopes in the atmosphere.
- Author
-
Gavini, M. B., primary and Kuroda, P. K., additional
- Published
- 1977
- Full Text
- View/download PDF
11. Temporal variations of212Pb in thunderstorms
- Author
-
Gavini, M. B., primary, Holloway, R. W., additional, Sherrill, R. D., additional, Inn, K. G. W., additional, and Kuroda, P. K., additional
- Published
- 1976
- Full Text
- View/download PDF
12. Structural analysis of the O-acetylated O-polysaccharide isolated from Salmonella Paratyphi A and used for vaccine preparation
- Author
-
Giuseppe Stefanetti, Paola Cescutti, Calman A. MacLennan, Massimiliano Gavini, Neil Ravenscroft, Francesca Micoli, Laura B. Martin, Ravenscroft, N., Cescutti, Paola, Gavini, M., Stefanetti, G., Maclennan, C. A., Martin, L. B., and Micoli, F.
- Subjects
Salmonella ,Magnetic Resonance Spectroscopy ,Lipopolysaccharide ,Salmonella Vaccines ,Rhamnose ,Bacterial polysaccharide structure ,medicine.disease_cause ,complex mixtures ,Biochemistry ,Salmonella paratyphi A, O-Polysaccharide, Bacterial polysaccharide structure, O-Acetylation ,Analytical Chemistry ,Microbiology ,chemistry.chemical_compound ,fluids and secretions ,Polysaccharides ,Conjugate vaccine ,Carbohydrate Conformation ,medicine ,O-Acetylation ,O-Polysaccharide ,Salmonella paratyphi A ,Acetylation ,Carbohydrate Sequence ,O Antigens ,Polysaccharides, Bacterial ,Vaccines, Conjugate ,Conjugate ,Vaccines ,biology ,Chemistry ,Immunogenicity ,Organic Chemistry ,Bacterial ,General Medicine ,Virology ,biology.protein ,bacteria ,Antibody - Abstract
Salmonella paratyphi A is increasingly recognized as a common cause of enteric fever cases and there are no licensed vaccines against this infection. Antibodies directed against the O-polysaccharide of the lipopolysaccharide of Salmonella are protective and conjugation of the O-polysaccharide to a carrier protein represents a promising strategy for vaccine development. O-Acetylation of S. paratyphi A O-polysaccharide is considered important for the immunogenicity of S. paratyphi A conjugate vaccines.Here, as part of a programme to produce a bivalent conjugate vaccine against both S. typhi and S. paratyphi A diseases, we have fully elucidated the O-polysaccharide structure of S. paratyphi A by use of HPLC–SEC, HPAEC–PAD/CD, GLC, GLC–MS, 1D and 2D-NMR spectroscopy. In particular, chemical and NMR studies identified the presence of O-acetyl groups on C-2 and C-3 of rhamnose in the lipopolysaccharide repeating unit, at variance with previous reports of O-acetylation at a single position. Moreover HR-MAS NMR analysis performed directly on bacterial pellets from several strains of S. paratyphi A also showed O-acetylation on C-2 and C-3 of rhamnose, thus this pattern is common and not an artefact from O-polysaccharide purification. Conjugation of the O-polysaccharide to the carrier protein had little impact on O-acetylation and therefore should not adversely affect the immunogenicity of the vaccine.
- Published
- 2015
13. Natural and artifically-produced radionuclides as atmospheric tracers
- Author
-
Gavini, M
- Published
- 1976
14. Development of a New Solid-Phase Extraction Base Method for Free Saccharide Content Estimation of Meningococcal Conjugate Vaccines.
- Author
-
De Ricco R, Rech F, Onnis V, Coccone SS, Scalia G, Marcozzi C, Gavini M, Beni S, Giannini S, Nompari L, Parlati C, Magagnoli C, Cianetti S, and Berti F
- Abstract
GlaxoSmithKline (GSK) is currently developing a fully liquid presentation to ease the administration of the licensed quadrivalent conjugate vaccine (Menveo) against meningococcal serogroup A, C, W, and Y (MenACWY) infections. Herein, we report a new method for determining the free saccharide (FS) content of CRM
197 -MenACWY conjugated antigens, with the aim of improving accuracy and reproducibility. Mathematical models have been used to support technical knowledge in reducing the need for experimental development. This results in an improved, faster, and platform-based technique for FS separation with one single pretreatment applicable to all antigens of the multivalent meningococcal vaccine., Competing Interests: The authors declare the following competing financial interest(s): All the authors are employees of the GSK group of companies. Francesco Berti is listed as an inventor on patents owned by the GSK group of companies., (© 2022 The Authors. Published by American Chemical Society.)- Published
- 2022
- Full Text
- View/download PDF
15. Effect of clinical pharmacist encounters in the transitional care clinic on 30-day re-admissions: A retrospective study.
- Author
-
Borhanjoo P, Kouamo P, Rahman M, Norton M, and Gavini M
- Abstract
Hospitalized patients who meet specific criteria at discharge are referred to the transitional care clinic team consisting of a nurse practitioner and/or physician and a clinical pharmacist. In collaboration with the providers, the pharmacist reviews medications for appropriateness, assesses adherence, recommends medication changes and provides education. The purpose of this study was to measure the effect of an outpatient transitional care clinical pharmacist on 30-day re-admissions in an urban setting serving a population of low socioeconomic status. After receiving IRB approval, this single-center retrospective study analyzed records of 573 patient visits of which nearly 75% included a clinical pharmacist interaction. Rates of 30-day re-admissions were not statistically different among the two groups, however, it was found that each added co-morbidity significantly increased the patients' 30-day re-admission rate by 26%., Competing Interests: Conflict of interest: All authors declare no conflicts of interest in this paper., (© 2019 the Author(s), licensee AIMS Press.)
- Published
- 2019
- Full Text
- View/download PDF
16. Who really manages our patients' medications? A study of inner city adults over 40 years of age.
- Author
-
Gavini M, Faber ES, Birnbaum A, and Sadovsky R
- Subjects
- Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Family, Female, Health Personnel statistics & numerical data, Humans, Male, Middle Aged, New York City, Outcome Assessment, Health Care, Patient-Centered Care, Prospective Studies, Surveys and Questionnaires, Urban Population, Caregivers statistics & numerical data, Drug Therapy methods, Medication Therapy Management statistics & numerical data, Pharmaceutical Preparations administration & dosage
- Abstract
Objectives: Primarily to determine how many of our adult patients receive significant assistance from another individual with medication management. Secondarily, to determine if the number of prescribed medications can be predictors of whether the patient receives significant assistance with medication management., Design: Cross-sectional survey study., Setting: A level 3 patient-centered medical home family practice clinic in an inner city university hospital in Brooklyn, New York., Participants: Patients 40 years of age and older coming for a regular clinic visit to see the primary care physician., Intervention: Administering the survey to the patients was the intervention. MAIN OUTCOME MEASURES: The number of patients who receive significant assistance with any phase of medication management was the main outcome measure., Results: Out of 143 patients surveyed, 61 patients (42.7%) received assistance with 1 or more phases of medication management; 38.5% (n = 55) of patients received help with phase 1 (ensuring that patients have medications at home). Of those 55 patients, 28 (50.9%) received help from family members, 22 (40%) received help from pharmacies, and 5 (9.1%) received help from home health aides or visiting nurses. Thirteen patients (9%) received help with phase 2 (arranging medications to help take them properly); 11 (84.6%) of them received help from family members. Twenty-three patients (16.1%) received help with phase 3 (reminding patients to take medications or handing them to the patient); 17 (73.9%) out of 23 received help from family members. There was a statistically significant trend (Mann-Whitney 2-sided test: P <0.001) showing a direct relationship between the number of medications and the need for assistance with 1 or more phases of medication management., Conclusion: Many adult patients receive help with 1 or more phases of medication management. Family members are the major source of assistance with medication management. Pharmacies also play an important role in making certain that patients have medications at home. Patients with a higher number of medications are more likely to receive assistance from others., (Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
17. Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman.
- Author
-
Faber ES, Gavini M, Ramirez R, and Sadovsky R
- Abstract
A 63-year-old woman previously stable on a regimen of atorvastatin 40 mg daily, carvedilol 25 mg twice daily, digoxin 0.125 mg daily, furosemide 40 mg daily, spironolactone 25 mg daily, rivaroxaban 15 mg daily, and enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril/valsartan (Entresto™) started. The patient received sacubitril/valsartan at 24/26 mg twice daily for heart failure; however, after 26 days she developed muscle and skin pain. Investigations revealed elevated creatine kinase and liver function tests, and rhabdomyolysis with raised transaminases was diagnosed. Sacubitril/valsartan and atorvastatin were discontinued and the patient was hydrated. She returned to baseline in 23 days and has not had any reoccurrence of rhabdomyolysis and elevated transaminases for 46 days. A Naranjo assessment score of 5 was obtained, indicating a probable relationship between the patient's rhabdomyolysis and her use of sacubitril/valsartan. The Drug Interaction Probability Scale score was 3, consistent with a possible interaction as a cause for the reaction, with sacubitril/valsartan as the precipitant drug and atorvastatin as the object drug., Competing Interests: Compliance with Ethical Standards Funding No sources of funding were used in the preparation of this report. Conflict of interest Eve S. Faber, Madhavi Gavini, Ronald Ramirez and Richard Sadovsky declare that they have no conflicts of interest that are directly relevant to the content of this report. Consent Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent may be requested for review from the corresponding author.
- Published
- 2016
- Full Text
- View/download PDF
18. Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
- Author
-
Goh YS, Necchi F, O'Shaughnessy CM, Micoli F, Gavini M, Young SP, Msefula CL, Gondwe EN, Mandala WL, Gordon MA, Saul AJ, and MacLennan CA
- Subjects
- Africa, Immunocompromised Host, Immunoglobulin A immunology, Immunoglobulin G immunology, Immunoglobulin M immunology, Lipopolysaccharides immunology, Serum Bactericidal Antibody Assay, Serum Bactericidal Test, Antibodies, Bacterial blood, HIV Infections immunology, Salmonella immunology, Salmonella Infections immunology
- Abstract
Background: Nontyphoidal strains of Salmonella are a leading cause of death among HIV-infected Africans. Antibody-induced complement-mediated killing protects healthy Africans against Salmonella, but increased levels of anti-lipopolysaccharide (LPS) antibodies in some HIV-infected African adults block this killing. The objective was to understand how these high levels of anti-LPS antibodies interfere with the killing of Salmonella., Methodology/principal Findings: Sera and affinity-purified antibodies from African HIV-infected adults that failed to kill invasive S. Typhimurium D23580 were compared to sera from HIV-uninfected and HIV-infected subjects with bactericidal activity. The failure of sera from certain HIV-infected subjects to kill Salmonella was found to be due to an inherent inhibitory effect of anti-LPS antibodies. This inhibition was concentration-dependent and strongly associated with IgA and IgG2 anti-LPS antibodies (p<0.0001 for both). IgG anti-LPS antibodies, from sera of HIV-infected individuals that inhibit killing at high concentration, induced killing when diluted. Conversely, IgG, from sera of HIV-uninfected adults that induce killing, inhibited killing when concentrated. IgM anti-LPS antibodies from all subjects also induced Salmonella killing. Finally, the inhibitory effect of high concentrations of anti-LPS antibodies is seen with IgM as well as IgG and IgA. No correlation was found between affinity or avidity, or complement deposition or consumption, and inhibition of killing., Conclusion/significance: IgG and IgM classes of anti-S. Typhimurium LPS antibodies from HIV-infected and HIV-uninfected individuals are bactericidal, while at very high concentrations, anti-LPS antibodies of all classes inhibit in vitro killing of Salmonella. This could be due to a variety of mechanisms relating to the poor ability of IgA and IgG2 to activate complement, and deposition of complement at sites where it cannot insert in the bacterial membrane. Vaccine trials are required to understand the significance of lack of in vitro killing by anti-LPS antibodies from a minority of HIV-infected individuals with impaired immune homeostasis.
- Published
- 2016
- Full Text
- View/download PDF
19. Simplified low-cost production of O-antigen from Salmonella Typhimurium Generalized Modules for Membrane Antigens (GMMA).
- Author
-
Meloni E, Colucci AM, Micoli F, Sollai L, Gavini M, Saul A, Di Cioccio V, and MacLennan CA
- Subjects
- Hydrolysis, Lipopolysaccharides chemistry, Lipopolysaccharides metabolism, Membranes chemistry, O Antigens chemistry, Vaccines chemistry, Membranes metabolism, O Antigens isolation & purification, O Antigens metabolism, Salmonella typhimurium chemistry, Salmonella typhimurium metabolism
- Abstract
The Novartis Vaccines Institute for Global Health is developing vaccines using outer membrane particles, known as Generalized Modules for Membrane Antigens (GMMA). These are blebs of outer membrane and periplasm, shed from the surface of living Gram-negative bacteria following the targeted deletion of proteins involved in maintaining the integrity of the inner and outer membranes. The current study investigates the use of GMMA as starting material for extraction of membrane components, focusing on the O-antigen polysaccharide portion of lipopolysaccharide from Salmonella Typhimurium. We show that the amount of O-antigen extracted from GMMA by acid hydrolysis is comparable to the quantity extracted from whole wild type bacteria, but with less protein and DNA contaminants. Compared to conventional purification, GMMA enabled a reduction in the number of purification steps required to obtain the O-antigen polysaccharide with the same purity. Purification processes from GMMA and bacteria were characterised by similar final yields. Use of GMMA as starting material provides the possibility to simplify the purification process of O-antigen, with a consequent decrease in manufacturing costs of O-antigen-based glyconjugate vaccines against Salmonella strains and potentially other Gram-negative bacteria., (Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Perceptions of care among high-risk geriatric patients, families, and caregivers in a patient-centered medical home.
- Author
-
Gavini M, Gennari AS, and Ruby CM
- Subjects
- Aged, Family, Humans, Patient Care Team, Patient Education as Topic, Risk, Caregivers, Patient-Centered Care, Perception
- Abstract
Objective: A survey was conducted by the pharmacy team to identify improvement areas in the delivery of care in high-risk patients at a patient-centered medical home (PCMH) at the University of Pittsburgh Medical Center (UPMC)., Design: This survey was a quality improvement project., Setting: The survey was conducted at UPMC Senior Care, a level-three accredited PCMH., Patients: The survey was conducted in a sample of preidentified high-risk patients., Interventions: Pharmacy performed a survey, analyzed responses for common themes, and conducted follow-up phone calls to determine the degree of goal-achievement and efficacy of educational materials provided during the initial survey., Main Outcome Measure: The primary goal for conducting the survey was to identify needed areas for improvement in three specific domains, namely, medication decisions, communication with providers, and goals of care., Results: Medication reviews were provided for 23 of 24 surveyed, leading to medication discrepancy resolution in 58%. Almost 80% of the respondents were satisfied with the team's communication. More than 85% of respondents verbalized the goals they wanted to achieve in three months. The follow-up phone calls were conducted in 20 of those initially surveyed. Only 5 patients did not meet their goals. The following improvement areas were identified: need to provide medication lists and correct medication inaccuracies, need for medication review, patient goals documentation, and patient education and the appropriate medium of education., Conclusion: Future appointments for high-risk patients at the PCMH should include the pharmacist. The team should focus education on families/caregivers and utilize alternate patient education methods.
- Published
- 2015
- Full Text
- View/download PDF
21. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
- Author
-
Micoli F, Romano MR, Tontini M, Cappelletti E, Gavini M, Proietti D, Rondini S, Swennen E, Santini L, Filippini S, Balocchi C, Adamo R, Pluschke G, Norheim G, Pollard A, Saul A, Rappuoli R, MacLennan CA, Berti F, and Costantino P
- Subjects
- Africa South of the Sahara epidemiology, Animals, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Glycoconjugates immunology, Humans, Magnetic Resonance Spectroscopy, Meningitis, Meningococcal immunology, Meningococcal Vaccines immunology, Mice, Neisseria meningitidis metabolism, Polysaccharides, Bacterial isolation & purification, Polysaccharides, Bacterial metabolism, Disease Outbreaks prevention & control, Glycoconjugates biosynthesis, Meningitis, Meningococcal epidemiology, Meningitis, Meningococcal prevention & control, Meningococcal Vaccines biosynthesis, Neisseria meningitidis genetics
- Abstract
Neisseria meningitidis is a major cause of bacterial meningitis worldwide, especially in the African meningitis belt, and has a high associated mortality. The meningococcal serogroups A, W, and X have been responsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the past 12 y. Currently no vaccine is available against meningococcal X (MenX). Because the development of a new vaccine through to licensure takes many years, this leaves Africa vulnerable to new epidemics of MenX meningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing rapidly, following the recent introduction of a glycoconjugate vaccine against serogroup A. Here, we report the development of candidate glycoconjugate vaccines against MenX and preclinical data from their use in animal studies. Following optimization of growth conditions of our seed MenX strain for polysaccharide (PS) production, a scalable purification process was developed yielding high amounts of pure MenX PS. Different glycoconjugates were synthesized by coupling MenX oligosaccharides of varying chain length to CRM197 as carrier protein. Analytical methods were developed for in-process control and determination of purity and consistency of the vaccines. All conjugates induced high anti-MenX PS IgG titers in mice. Antibodies were strongly bactericidal against African MenX isolates. These findings support the further development of glycoconjugate vaccines against MenX and their assessment in clinical trials to produce a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be prevented by available vaccines.
- Published
- 2013
- Full Text
- View/download PDF
22. Purification of antibodies to O antigen of Salmonella Typhimurium from human serum by affinity chromatography.
- Author
-
O'Shaughnessy CM, Micoli F, Gavini M, Goodall M, Cobbold M, Saul A, and Maclennan CA
- Subjects
- Adipates chemistry, Adipates immunology, Adult, Animals, Antibodies, Bacterial isolation & purification, Chromatography, Affinity instrumentation, Chromatography, High Pressure Liquid, Enzyme-Linked Immunosorbent Assay, Humans, O Antigens chemistry, Rabbits, Salmonella Infections blood, Salmonella Infections microbiology, Serum microbiology, Antibodies, Bacterial immunology, Chromatography, Affinity methods, O Antigens immunology, Salmonella Infections immunology, Salmonella typhimurium immunology, Serum immunology
- Abstract
Nontyphoidal Salmonellae (NTS) are a common cause of bacteraemia in children and HIV-infected adults in Sub-Saharan Africa. We have previously shown that antibodies play a key role in both bactericidal and cellular mechanisms of immunity to NTS, but found that high concentrations of antibody to Salmonella Typhimurium O antigen (OAg) in the serum of some HIV-infected African adults is associated with impaired killing of NTS. To further investigate the function of antibodies to the OAg of NTS, we developed a method to purify these antibodies from human serum by affinity chromatography. Purified Salmonella Typhimurium OAg was activated with adipic acid dihydrazide (ADH) via two different chemistries before linking to N-hydroxysuccinamide-Sepharose resin: one ADH molecule was introduced per OAg chain on its terminal 3-deoxy-D-manno-octulosonic acid sugar (OAg-ADH), or multiple ADH molecules were attached along the OAg chain after oxidation with sodium periodate (OAgoxADH). Both resulting columns worked well when tested with commercial polyclonal anti-O:4,5 antibodies from rabbit serum. Over 90% of the applied antibodies bound to the resin and 89% of these antibodies were then eluted as detected by ELISA. OAg-ADH was preferred as the method for OAg derivatisation as it does not modify the saccharide chain and can be applied to OAg from different bacteria. Both columns were able to bind OAg-specific antibodies in human serum, but antibody recovery was initially low. Different elution buffers were tested and different amounts of OAg-ADH were linked to the resin to improve the yield. Optimal recovery (51%) was obtained by loading 1mg of activated OAg per ml of resin and eluting with 0.1M glycine, 0.1M NaCl pH2.4. The column matrix could be regenerated following elution with no detectable loss in performance for over ten uses. This method offers the potential to purify antibodies to Salmonella OAg from polyclonal serum following vaccination or natural exposure to Salmonella and so investigate the functionality and diversity of the antibody response to OAg., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
23. O:2-CRM(197) conjugates against Salmonella Paratyphi A.
- Author
-
Micoli F, Rondini S, Gavini M, Lanzilao L, Medaglini D, Saul A, and Martin LB
- Subjects
- Animals, Bacterial Proteins immunology, Bacterial Proteins therapeutic use, Carbohydrate Sequence, Female, Humans, Mice, Molecular Sequence Data, O Antigens immunology, O Antigens therapeutic use, Paratyphoid Fever blood, Paratyphoid Fever immunology, Paratyphoid Fever veterinary, Salmonella paratyphi A chemistry, Typhoid-Paratyphoid Vaccines immunology, Typhoid-Paratyphoid Vaccines therapeutic use, Vaccines, Conjugate immunology, Vaccines, Conjugate therapeutic use, Bacterial Proteins chemistry, O Antigens chemistry, Paratyphoid Fever prevention & control, Salmonella paratyphi A immunology, Typhoid-Paratyphoid Vaccines chemistry, Vaccines, Conjugate chemistry
- Abstract
Enteric fevers remain a common and serious disease, affecting mainly children and adolescents in developing countries. Salmonella enterica serovar Typhi was believed to cause most enteric fever episodes, but several recent reports have shown an increasing incidence of S. Paratyphi A, encouraging the development of a bivalent vaccine to protect against both serovars, especially considering that at present there is no vaccine against S. Paratyphi A. The O-specific polysaccharide (O:2) of S. Paratyphi A is a protective antigen and clinical data have previously demonstrated the potential of using O:2 conjugate vaccines. Here we describe a new conjugation chemistry to link O:2 and the carrier protein CRM(197), using the terminus 3-deoxy-D-manno-octulosonic acid (KDO), thus leaving the O:2 chain unmodified. The new conjugates were tested in mice and compared with other O:2-antigen conjugates, synthesized adopting previously described methods that use CRM(197) as carrier protein. The newly developed conjugation chemistry yielded immunogenic conjugates with strong serum bactericidal activity against S. Paratyphi A.
- Published
- 2012
- Full Text
- View/download PDF
24. Results of statistical analysis of blend and dosage unit content uniformity data obtained from the Product Quality Research Institute Blend Uniformity Working Group data-mining effort.
- Author
-
Boehm G, Clark J, Dietrick J, Foust L, Garcia T, Gavini M, Geoffroy JM, Jimenez P, Mergen G, Muzzio F, Planchard J, Prescott J, Timmermans J, Takiar N, and Whiteman D
- Subjects
- Drug Compounding standards, Guidelines as Topic, Normal Distribution, Powders analysis, Powders standards, Quality Control, Reproducibility of Results, Sample Size, Tablets analysis, Tablets standards, United States, United States Food and Drug Administration, Dosage Forms standards, Research standards, Technology, Pharmaceutical legislation & jurisprudence, Technology, Pharmaceutical standards, Technology, Pharmaceutical statistics & numerical data
- Published
- 2004
25. The use of stratefied sampling of blend and dosage units to demonstrate adequacy of mix for powder blends.
- Author
-
Boehm G, Clark J, Dietrick J, Foust L, Garcia T, Gavini M, Gelber L, Geoffroy JM, Hoblitzell J, Jimenez P, Mergen G, Muzzio F, Planchard J, Prescott J, Timmermans J, and Takiar N
- Subjects
- Chemistry, Pharmaceutical, Drug Industry legislation & jurisprudence, Drug Industry standards, Guidelines as Topic, Powders chemistry, Quality Control, Sample Size, Technology, Pharmaceutical legislation & jurisprudence, United States, United States Food and Drug Administration, Powders standards, Technology, Pharmaceutical standards
- Abstract
In response to concerns expressed by applicants regarding inconsistent policies in establishing blend uniformity acceptance criteria to demonstrate adequacy of mix, the FDA Office of Generic Drugs (OGD) issued the draft document Guidance for Industry, ANDAs: Blend Uniformity Analysis (August 1999). Both generic and innovator pharmaceutical companies raised a number of concerns following the publication of this document. As a result, the Product Quality Research Institute (PQRI) Blend Uniformity Working Group (BUWG) was established in February 2000. One of the primary goals of this group was to draft a scientifically based alternative to the OGD document. The resulting recommendation addresses both FDA and industry concerns by substantially enhancing product quality assurance without increasing regulatory burden. The PQRI BUWG recommends that these blend and dosage unit uniformity requirements be administered uniformly throughout the industry. PQRI submitted the following recommendation to the FDA on December 31, 2002, providing the Agency with an alternative strategy to consider when drafting future regulatory policy to assess blend and dosage unit uniformity.
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.